samedan logo

home > ebr > spring 2021 > beyond cold
European Biopharmaceutical Review

Beyond Cold

Without a doubt, 2020 was an unusual year. The SARSCoV-2 pandemic reshaped how we work, live, learn, and interact at every level. The global response, however, was unprecedented. The imperative to contain the virus pushed the vaccine industry into the public spotlight and the outcome was disruptive: a new generation of vaccines emerged that has redefined immunisation strategies.

A New Era in Vaccine Storage

Vaccines based on novel mRNA and viral vector technologies are in line to bring the world back to normalcy. Developed, tested, and approved in record time, these vaccines have changed how industry produces, manages, and – above all – moves immunisations through the cold chain from manufacturing sites to anxiously waiting end users. Within the span of just 11 months, the transport and storage of vaccines at -70°C became a global priority. Before last year, ultra-low temperature (ULT) had only been used for the highly localised delivery of trial vaccines during Ebola outbreaks.

Until now, most vaccines were commonly stored between 2°C and 8°C worldwide. Consequently, the existing cold chain infrastructure built on standard refrigerators and freezers was insufficient to accommodate these new ULT storage needs. In anticipation and support of these new vaccine modes, and facing the largest immunisation campaign in human history, cold chain infrastructure is expanding to reach far below sub-zero temperatures and adding storage facilities to accommodate massive numbers of doses.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

Dr Alex Esmon is Senior Director/General Manager for Cold Storage at the laboratory products division of Thermo Fisher Scientific. With a PhD in Molecular Biology from the University of Missouri, Columbia, US, Dr Esmon has over 13 years of experience in industry and has overseen almost all aspects of managing products for cold storage and cryopreservation.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Mogrify and Astellas Announce Collaboration to Conduct Research on In Vivo Regenerative Medicine Approaches to Address Sensorineural Hearing Loss

Cambridge, UK, Tokyo, Japan, 05 July 2022: Mogrify Limited (CEO: Darrin M. Disley, Ph.D., “Mogrify®”), a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”), a leader in regenerative medicine, today announced that they have executed a collaborative research agreement on in vivo regenerative medicine approaches to address sensorineural hearing loss.
More info >>

White Papers

Points to Consider When Developing a TMF (Trial Master File) Strategy

Phlexglobal Ltd

Many organizations are currently outsourcing clinical trial activities to one or more contract research organizations (CROs). This strategy enables companies to leverage specialized expertise and take advantage of flexible resourcing throughout the conduct of a clinical trial. Outsourcing minimizes the costs of recruiting experts, building a team and maintaining an infrastructure. However, it can also add complexity as the organization looks to meets its compliance obligations regarding clinical trial documentation. The documentation referred to in Article 15(5) of Directive 2001/20/EC as the trial master file shall consist of essential documents, which enable both the conduct of a clinical trial and the quality of the data produced to be evaluated.1 This essential study specific documentation is also known as the TMF. As organizations try to minimize their reliance on paper files, the electronic TMF (eTMF) has emerged. A current industry initiative to standardize the organization of this content is known as the TMF Reference Model. This model is helping standardization efforts across paper and electronic systems. As companies implement outsourcing strategies, CROs and sponsor organizations look for a common foundation on which to build their TMF capabilities. The following paper outlines some of the challenges organizations face when outsourcing clinical trial activities to multiple contract research organizations and a strategy to facilitate partnering and management of trial information between sponsors and CROs.
More info >>




©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement